BLU-285 is a potent and selective inhibitor of PDGFR D842V and KIT Exon 17 mutants and is being developed as a highly targeted therapy for SM, a disorder of the mast cells in which a KIT Exon 17 mutation is the primary driver of disease.
For research use only. We do not sell to patients.